Expression of activator protein-1 (AP-1) family members in breast cancer

BMC Cancer

Amirhossein Kharman-Biz²  Hui Gao¹  Reza Ghiasvand³  Chunyan Zhao¹  Kazem Zendehdel²  Karin Dahlman-Wright¹ 

[1] Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, S-14183, Huddinge, Sweden

[2] Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

[3] Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

关键词: Progesterone receptor;    Estrogen receptor;    Breast cancer;    AP-1 family members;   

Others  :  1079550
DOI  :  10.1186/1471-2407-13-441

 received in 2013-04-05, accepted in 2013-09-25,  发布年份 2013

【 摘 要 】

Background

The activator protein-1 (AP-1) transcription factor is believed to be important in tumorigenesis and altered AP-1 activity was associated with cell transformation. We aimed to assess the potential role of AP-1 family members as novel biomarkers in breast cancer.

Methods

We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37 adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status. Expression levels of Ubiquitin C (UBC) were used for normalization. Protein expression of AP-1 members was assessed using Western blot analysis in a subset of tumors. We used student’s t-test, one-way ANOVA, logistic regression and Pearson’s correlation coefficient for statistical analyses.

Results

We found significant differences in the expression of AP-1 family members between tumor and adjacent non-tumor tissues for all AP-1 family members except Fos B. Fra-1, Fra-2, Jun-B and Jun-D mRNA levels were significantly higher in tumors compared to adjacent non-tumor tissues (p < 0.001), whilst c-Fos and c-Jun mRNA levels were significantly lower in tumors compared with adjacent non-tumor tissues (p < 0.001). In addition, Jun-B overexpression had outstanding discrimination ability to differentiate tumor tissues from adjacent non-tumor tissues as determined by ROC curve analysis. Moreover, Fra-1 was significantly overexpressed in the tumors biochemically classified as ERα negative (p = 0.012) and PR negative (p = 0.037). Interestingly, Fra-1 expression was significantly higher in triple-negative tumors compared with luminal carcinomas (p = 0.01).

Conclusions

Expression levels of Fra-1 and Jun-B might be possible biomarkers for prognosis of breast cancer.

【 授权许可】

   
2013 Kharman-Biz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Canc J Clin 2005, 55:74-108.
• [2]Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874.
• [3]Sawyers CL: The cancer biomarker problem. Nature 2008, 452(7187):548-552.
• [4]Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR, Folsom AR: Progesterone and estrogen receptors and mammary neoplasia in the Iowa women's health study: how many kinds of breast cancer are there? Canc Epidemiol Biomarkers Prev 1995, 4(4):319-326.
• [5]Hanna W: Testing for HER2 status. Oncology 2001, 61(Suppl 2):22-30.
• [6]Weigel MT, Dowsett M: Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Canc 2010, 17(4):R245-R262.
• [7]Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Canc 2002, 2(2):101-112.
• [8]Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993, 15(1):17-35.
• [9]Huang W-Y, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG: Hormone-related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. Am J Epidemiol 2000, 151(7):703-714.
• [10]Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA: International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006, 58(4):773-781.
• [11]Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000, 74(5):311-317.
• [12]Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Loning T, Bamberger AM: The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Canc Res Treat 2004, 86(2):139-152.
• [13]Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991, 1072(2–3):129-157.
• [14]Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Canc 1999, 84(5):533-538.
• [15]Langer S, Singer CF, Hudelist G, Dampier B, Kaserer K, Vinatzer U, Pehamberger H, Zielinski C, Kubista E, Schreibner M: Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol 2006, 27(4):345-352.
• [16]Milde-Langosch K, Janke S, Wagner I, Schroder C, Streichert T, Bamberger AM, Janicke F, Loning T: Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Canc Res Treat 2008, 107(3):337-347.
• [17]Logullo AF, Stiepcich MM, Osorio CA, Nonogaki S, Pasini FS, Rocha RM, Soares FA, Brentani MM: Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology 2011, 58(4):617-625.
• [18]Schroder C, Schumacher U, Muller V, Wirtz RM, Streichert T, Richter U, Wicklein D, Milde-Langosch K: The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Canc 2010, 46(9):1650-1660.
• [19]LaValley MP: Logistic regression. Circulation 2008, 117(18):2395-2399.
• [20]O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC: Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study. Clin Canc Res 2010, 16(24):6100-6110.
• [21]El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, Shamseddine AI: Effects of young age at presentation on survival in breast cancer. BMC Canc 2006, 6:194. BioMed Central Full Text
• [22]Montazeri A, Ebrahimi M, Mehrdad N, Ansari M, Sajadian A: Delayed presentation in breast cancer: a study in Iranian women. BMC Women's Health 2003, 3(1):4. BioMed Central Full Text
• [23]Mousavi M, Montazeri A, Mohagheghi MA, Mousavi Jarrahi A, Harirchi I, Najafi M, Ebrahimi M: Breast Cancer in Iran: An Epidemiological Review. Breast J 2007, 13(4):383-391.
• [24]Mousavi SM, Zheng T, Dastgiri S, Miller AB: Age distribution of breast cancer in the middle East, implications for screening. Breast J 2009, 15(6):677-679.
• [25]Smith LM, Birrer MJ, Stampfer MR, Brown PH: Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Canc Res 1997, 57(14):3046-3054.
• [26]Chiappetta G, Ferraro A, Botti G, Monaco M, Pasquinelli R, Vuttariello E, Arnaldi L, Di Bonito M, D'Aiuto G, Pierantoni GM, et al.: FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Canc 2007, 7:17. BioMed Central Full Text
• [27]Belguise K, Milord S, Galtier F, Moquet-Torcy G, Piechaczyk M, Chalbos D: The PKCtheta pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene 2012, 31(47):4889-4897.
• [28]Belguise K, Kersual N, Galtier F, Chalbos D: FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 2005, 24(8):1434-1444.
• [29]Milde-Langosch K, Kappes H, Riethdorf S, Loning T, Bamberger AM: FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Canc Res Treat 2003, 77(3):265-275.